Rather, they should be used in patients with symptomatic anemia, in high-risk patients (e.g., those undergoing high-dose chemo-or radiotherapy with the cumulative decrease of Hb levels) or asymptomatic patients with comorbidities, but not in multiple alloantibody patients. The gene discussed is GSTM1; the disease is anemia.